Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer

@article{Katz2017CheckpointIT,
  title={Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer},
  author={H. Katz and E. Wassie and M. Alsharedi},
  journal={Medical Oncology},
  year={2017},
  volume={34},
  pages={1-11}
}
  • H. Katz, E. Wassie, M. Alsharedi
  • Published 2017
  • Medicine
  • Medical Oncology
  • Bladder cancer is the most common malignancy involving the genitourinary system (Siegel et al. in CA Cancer J Clin, 66:7–30, 2016). In the USA, it is the fifth most common cancer and approximately 79,000 new cases will be diagnosed in 2017 (Siegel et al. in CA Cancer J Clin, 66:7–30, 2016). The mortality from bladder cancer is approximately 17,000 deaths each year (Siegel et al. in CA Cancer J Clin, 66:7–30, 2016). The incidence rate for bladder cancer is higher in men compared to women. Risk… CONTINUE READING
    21 Citations
    Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab
    • 45
    • PDF
    Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches
    • 13
    Avelumab: a new standard for treating metastatic Merkel cell carcinoma
    • 12
    ZSCAN16 promotes proliferation, migration and invasion of bladder cancer via regulating NF-kB, AKT, mTOR, P38 and other genes.
    • 1

    References

    SHOWING 1-10 OF 32 REFERENCES
    Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions
    • 32
    • Highly Influential
    • PDF
    Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma
    • 1,289
    • PDF
    Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
    • 763
    Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.
    • C. Massard, M. Gordon, +16 authors N. Segal
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2016
    • 516
    • PDF
    Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, phase 1/2 trial
    • 246